Ed Mathers is a General Partner at New Enterprise Associates (NEA). See sector focus and contact routes.
Ed Mathers is a General Partner at New Enterprise Associates (NEA), where he has worked since 2008 on the healthcare team focusing on biotechnology and specialty pharmaceuticals. Before joining NEA, he served as Executive Vice President of Corporate Development and Venture at MedImmune, helping execute its $15.6 billion sale to AstraZeneca, and previously spent 15 years at Glaxo Wellcome. His investment thesis targets early-stage biopharmaceutical companies developing novel therapeutics, with interests in gene therapy, RNA editing, nonviral gene therapy, and immunology. He invests across seed/early and growth stages in the healthcare sector, typically at Series A and Series B, with check sizes ranging from $2.0 million to $50.0 million. Notable portfolio companies include Lumena (acquired by Shire), Ziarco (acquired by Novartis), Motus Therapeutics (acquired by Allergan), and Akouos (acquired by Lilly). Mathers serves on the boards of over a dozen life science companies, including Affinia Therapeutics, Akouos, and Rhythm Pharmaceuticals, reflecting his deep operational involvement. While no public writing is cited in the search results, his d
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Washington.
Investors like Ed Mathers · Full investor directory · Investor access · Company funding database